DaVita Inc. $DVA Shares Sold by Franklin Resources Inc.

Franklin Resources Inc. lowered its stake in shares of DaVita Inc. (NYSE:DVA) by 51.2% during the second quarter, Holdings Channel reports. The fund owned 24,988 shares of the company’s stock after selling 26,269 shares during the period. Franklin Resources Inc.’s holdings in DaVita were worth $3,560,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of DVA. MAI Capital Management increased its holdings in DaVita by 23.4% during the 2nd quarter. MAI Capital Management now owns 438 shares of the company’s stock worth $62,000 after purchasing an additional 83 shares during the period. Entropy Technologies LP purchased a new stake in shares of DaVita during the second quarter worth approximately $1,632,000. Swiss National Bank increased its stake in shares of DaVita by 4.8% during the second quarter. Swiss National Bank now owns 133,300 shares of the company’s stock worth $18,989,000 after buying an additional 6,100 shares during the period. Prudential PLC raised its holdings in DaVita by 267.5% in the second quarter. Prudential PLC now owns 7,994 shares of the company’s stock valued at $1,139,000 after acquiring an additional 5,819 shares in the last quarter. Finally, Empowered Funds LLC lifted its stake in DaVita by 805.8% in the second quarter. Empowered Funds LLC now owns 61,703 shares of the company’s stock worth $8,790,000 after acquiring an additional 54,891 shares during the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DVA has been the topic of a number of analyst reports. Barclays reduced their price objective on shares of DaVita from $149.00 to $143.00 and set an “equal weight” rating on the stock in a report on Thursday, October 30th. Truist Financial set a $140.00 target price on DaVita in a report on Tuesday, October 14th. Cowen reaffirmed a “hold” rating on shares of DaVita in a report on Monday, November 3rd. Zacks Research upgraded DaVita from a “strong sell” rating to a “hold” rating in a report on Friday, November 28th. Finally, TD Cowen cut their target price on DaVita from $154.00 to $133.00 and set a “hold” rating on the stock in a research report on Monday, November 3rd. Six analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, DaVita presently has an average rating of “Reduce” and a consensus price target of $148.00.

DaVita Stock Performance

Shares of DVA stock opened at $119.08 on Wednesday. The stock’s 50-day moving average is $124.51 and its two-hundred day moving average is $133.29. DaVita Inc. has a 1 year low of $113.97 and a 1 year high of $179.60. The firm has a market cap of $8.41 billion, a price-to-earnings ratio of 12.26, a PEG ratio of 0.90 and a beta of 1.00.

DaVita (NYSE:DVA) last announced its earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). The firm had revenue of $3.42 billion during the quarter, compared to analyst estimates of $3.43 billion. DaVita had a net margin of 5.80% and a negative return on equity of 13,370.89%. The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period last year, the company earned $2.59 earnings per share. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. As a group, research analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.